why choose us

First received: March 22, 2024

Clinical Trial: Oral Azacitidine Maintenance Post-CPX 351

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Acute Myeloid Leukemia

Study Type: OBSERVATIONAL


Official Title: Maintenance Treatment With Oral Azacitidine for Patients With de Novo AML Including t-AML and AML-MRC in First Remission After CPX-351

Brief Summary: Approximately 10% of patient develop AML after chemotherapy or radiation for unrelated disease (t-AML) and 20% have AML with an antecedent hematologic disorder (AML-MRC). CPX-351 (Vyxeos), a liposomal formulation of a fixed molar ratio (1:5) daunorubicin and cytarabine, has been approved for treatment of adults with newly diagnosed t-AML or AML-MRC. CPX-351 significantly improved median overall survival.Although induction chemotherapy results in remission in many older patients with AML, relapse is common and…

Read more